Regeneron Pharmaceuticals (NASDAQ:REGN) Lifted to Strong-Buy at StockNews.com

StockNews.com upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a buy rating to a strong-buy rating in a research note issued to investors on Wednesday.

REGN has been the subject of several other reports. Truist Financial reiterated a buy rating and issued a $1,200.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. TD Cowen upped their price target on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a buy rating in a research report on Tuesday, July 23rd. BMO Capital Markets restated an outperform rating and set a $1,300.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. Morgan Stanley cut their price target on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an overweight rating for the company in a research report on Thursday, July 11th. Finally, Leerink Partnrs lowered shares of Regeneron Pharmaceuticals from a strong-buy rating to a hold rating in a research report on Tuesday, September 24th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, sixteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of Moderate Buy and an average price target of $1,119.00.

Regeneron Pharmaceuticals Stock Up 1.7 %

Shares of NASDAQ:REGN opened at $1,015.67 on Wednesday. Regeneron Pharmaceuticals has a 52-week low of $769.19 and a 52-week high of $1,211.20. The firm has a fifty day moving average of $1,118.02 and a 200 day moving average of $1,038.38. The firm has a market capitalization of $111.91 billion, a PE ratio of 30.01, a price-to-earnings-growth ratio of 3.45 and a beta of 0.12. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The company had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.38 billion. During the same period in the previous year, the business earned $8.79 earnings per share. The firm’s quarterly revenue was up 12.3% compared to the same quarter last year. As a group, research analysts anticipate that Regeneron Pharmaceuticals will post 37.82 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at $18,447,575.65. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Jason Pitofsky sold 487 shares of the company’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the completion of the sale, the vice president now owns 4,204 shares in the company, valued at approximately $4,498,280. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.48% of the stock is owned by insiders.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of institutional investors have recently made changes to their positions in REGN. Global Assets Advisory LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the first quarter valued at approximately $339,594,000. Capital International Investors grew its holdings in shares of Regeneron Pharmaceuticals by 7.3% during the first quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock valued at $3,011,640,000 after buying an additional 213,038 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Regeneron Pharmaceuticals by 25.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock valued at $868,757,000 after buying an additional 184,561 shares during the last quarter. TD Asset Management Inc grew its holdings in shares of Regeneron Pharmaceuticals by 162.9% during the first quarter. TD Asset Management Inc now owns 269,511 shares of the biopharmaceutical company’s stock valued at $259,402,000 after buying an additional 166,998 shares during the last quarter. Finally, Swedbank AB purchased a new stake in shares of Regeneron Pharmaceuticals during the first quarter valued at approximately $129,257,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.